Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of... see more

Recent & Breaking News (NDAQ:MCRB)

Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting

Business Wire May 11, 2021

Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

Business Wire May 4, 2021

Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021

Business Wire April 28, 2021

Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit

Business Wire April 15, 2021

Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer

PR Newswire March 30, 2021

Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference

Business Wire March 12, 2021

 Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma

Business Wire March 8, 2021

Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates

Business Wire March 2, 2021

Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis

Business Wire March 2, 2021

Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

Business Wire February 26, 2021

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target

PR Newswire February 25, 2021

Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021

Business Wire February 24, 2021

Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium

Business Wire January 19, 2021

Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology

Business Wire January 6, 2021

Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

Business Wire January 6, 2021

Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

Business Wire November 19, 2020

Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates

Business Wire November 9, 2020

Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

Business Wire November 6, 2020

Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020

Business Wire November 2, 2020

Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer

Business Wire October 22, 2020